Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lumara Health, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years.
Singleton gestation.
Gestational age 16 weeks 0 days to 20 weeks 6 days.
Previous singleton spontaneous preterm delivery
You may not be if
Multifetal gestation.
Known major fetal anomaly or fetal demise.
Progestin treatment in any form in the 4 weeks prior to study entry.
Heparin therapy during current pregnancy or history of thromboembolic disease.
Maternal medical/obstetrical complications including hypertension requiring medication or seizure disorder.
uterine anomaly other than fibroids
Known hypersensitivity to hydroxyprogesterone caproate injection or its components.
Any significant medical disorder that, in the opinion of the investigator, would be a contraindication to the use of the drug or would preclude accurate evaluation of the subject's condition or outcome or compromise the subject's safety in the study.
Clareo Health | Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood
